deltatrials
Completed PHASE1 INTERVENTIONAL 4-arm NCT02818686

TD-1473 for Active Ulcerative Colitis (UC)

A Phase 1b Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Plasma Exposure of TD-1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis

Sponsor: Theravance Biopharma

Conditions Ulcerative Colitis, Active Moderate Ulcerative Colitis, Active Severe
Interventions Placebo TD-1473
Updated 14 times since 2017 Last updated: Sep 28, 2021 Started: Oct 3, 2016 Primary completion: Mar 29, 2018 Completion: Mar 29, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Ulcerative Colitis, Active Moderate and Ulcerative Colitis, Active Severe and is currently completed. Theravance Biopharma leads this study, which shows 14 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Jan 2020 · 15 months · monthly snapshot~Jan 2020 – ~Sep 2020 · 8 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Jul 2024 · 33 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Oct 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jan 2021 — Oct 2021 [monthly]

    Completed PHASE1

▶ Show 9 earlier versions

  1. Oct 2020 — Jan 2021 [monthly]

    Completed PHASE1

  2. Sep 2020 — Oct 2020 [monthly]

    Completed PHASE1

  3. Jan 2020 — Sep 2020 [monthly]

    Completed PHASE1

  4. Oct 2018 — Jan 2020 [monthly]

    Completed PHASE1

  5. Sep 2018 — Oct 2018 [monthly]

    Completed PHASE1

    Status: Recruiting → Completed

  6. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  7. Jun 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  8. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE1

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Theravance Biopharma
Data source: Theravance Biopharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations